The US FDA advises sponsors to look at a variety of sources to determine if a Risk Evaluation and Mitigation Strategy (REMS) is meeting its goal of lessening a drug's risks, including drug utilization data, stakeholder surveys and observational and epidemiology data.
The agency describes how to develop a REMS Assessment Plan in a draft guidance released Jan. 24. The document...